All studies
RecruitingPHASE1INTERVENTIONAL

A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis

This research is looking at a new medicine called LY4213663 for people with rheumatoid arthritis (RA). The main aim is to find out how safe it is and what side effects it might have in both healthy people and those with RA. Scientists also want to understand how the body uses and processes this new medicine. The medicine will be given either as a shot under the skin or through a drip into a vein. Participants will have blood tests to see how the medicine acts in their bodies. The study will last about 33 weeks, not including the first check-up period. It's a 'Phase 1' study, which means it's one of the first times this medicine is being tested in people.

At a glance

Status
Recruiting
Phase
PHASE1
Sponsor
Eli Lilly and Company
Enrolment target
141
Start
02 Dec 2025
Estimated completion
01 Mar 2028

What is this study about?

This study is about a new medicine called LY4213663, which is being developed to treat rheumatoid arthritis (RA). RA is a condition where your body's immune system mistakenly attacks your own healthy tissues, causing pain, swelling, and stiffness in your joints. Finding new and better treatments is very important for people living with RA.

The main goal of this study is to learn more about this new medicine. Specifically, researchers want to see if it's safe to use, what side effects people might experience, and how the body handles the medicine. They also want to understand how the medicine affects the body once it's taken. By carefully studying healthy volunteers first, and then people with RA, scientists can gather important information in a safe and step-by-step way.

Understanding how a new medicine works and ensuring it's safe is the first important step before it can be made widely available. This 'Phase 1' study is crucial for gathering this early information and helping decide if the medicine should be studied further in larger groups of people. Every new treatment starts with studies like this one, carefully checking for safety and how the medicine behaves in the body.

Key takeaways

  • This study is testing a new medicine (LY4213663) for rheumatoid arthritis.
  • It aims to find out if the medicine is safe and what side effects it might cause.
  • Both healthy people and those with rheumatoid arthritis can take part.
  • The medicine will be given either as a shot or through a drip.
  • The study involves blood tests and lasts about 33 weeks.
  • Your health will be closely monitored throughout the study.

Who may be eligible?

To join this study, you'd generally need to be between 18 and 75 years old. Your body mass index (BMI), which is a measure of your weight compared to your height, needs to be within a certain range.

If you have rheumatoid arthritis, you must have been diagnosed with it for at least three months. It's also important that your RA isn't too severe (not 'Class 4' according to a standard medical classification). You should not have any current or recent serious infections, and your heart health will be checked.

If you are a healthy person interested in taking part, you should not have any major long-term health problems with your heart, lungs, liver, kidneys, or other major body systems that could affect how the medicine works in your body.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. Are you between 18 and 75 years old?
  2. Is your weight for your height (BMI) within a healthy range?
  3. If you have RA, have you been diagnosed for at least 3 months?
  4. Do you currently have any serious active infections?
  5. Do you have any major heart problems?
  6. Do you have severe rheumatoid arthritis (Class 4)?
Answer every question to see your result.

What does participation involve?

If you decide to take part, you'll first have a screening visit to check if the study is right for you. If you qualify, you will receive the study medicine, LY4213663, either as a small injection under your skin or through a drip directly into a vein in your arm. Some participants might receive a placebo, which looks like the study medicine but contains no active ingredient. This helps researchers compare the effects of the real medicine.

You'll have regular blood tests to help the study team understand how the medicine is working in your body and how your body is responding to it. You will also have check-ups to monitor your health and look for any side effects. The total time you'll be involved in the study, not including the initial screening, will be around 33 weeks.

Potential risks and benefits

Taking part in any medical study carries potential benefits and risks. You might benefit from receiving a new medicine for your rheumatoid arthritis, though it's important to remember that this medicine is still in early development, and we don't yet fully know its effects. There's also the chance you might receive a placebo. Potential risks include side effects from the study medicine, which will be carefully monitored. You will be told about all known risks before you agree to take part. It's important to know that you are free to leave the study at any time, for any reason, without it affecting your usual medical care.

Locations (10)

  • Pinnacle Research Group, LLC
    Verified postcode
    Anniston, United States· Recruiting
  • Arizona Research Center
    Verified postcode
    Phoenix, United States· Recruiting
  • Clinical Research of West Florida, Inc. (Clearwater)
    Verified postcode
    Clearwater, United States· Recruiting
  • GNP Research at Mark Jaffe, MD
    Verified postcode
    Cooper City, United States· Recruiting
  • Fortrea Clinical Research Unit
    Verified postcode
    Daytona Beach, United States· Recruiting
  • AGA Clinical Trials
    Verified postcode
    Hialeah, United States· Recruiting
  • Advanced Pharma CR, LLC
    Verified postcode
    Miami, United States· Recruiting
  • Floridian Clinical Research
    Verified postcode
    Miami Lakes, United States· Recruiting
  • Oasis Clinical Research
    Verified postcode
    Las Vegas, United States· Recruiting
  • Universitätsklinikum Charité
    Verified postcode
    Berlin, Germany· Not yet recruiting

Common questions

What is rheumatoid arthritis?

Rheumatoid arthritis (RA) is a condition where your body's immune system attacks your joints, causing pain, swelling, and stiffness.

What does 'Phase 1' mean?

Phase 1 means this is one of the first times the new medicine is being tested in people to check its safety and how it works in the body.

What is a placebo?

A placebo looks just like the study medicine but doesn't contain any active drug. It helps researchers compare the effects of the real medicine.

How will the medicine be given?

The medicine will be given either as an injection under the skin (subcutaneously) or through a drip into a vein (intravenously).

How long will the study last?

The study will last about 33 weeks, not including the initial check-up period.

How to find out more

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "A Study of LY4213663 in Healthy Participants and Participant…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.